NCT04718415View on ClinicalTrials.gov

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 23, 2021

Primary Completion Date

January 1, 2023

Study Completion Date

January 23, 2027

Conditions
Oral Squamous Cell CarcinomaOropharyngeal Squamous Cell Carcinoma
Interventions
DRUG

sintilimab, paclitaxel, carboplatin

Patients receive sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 - 4 courses in the absence of disease progression or unacceptable toxicity.

PROCEDURE

Surgical resection

Surgical therapy will be at the discretion of the treating surgeon per standard of care.

Trial Locations (2)

510000

Sun Yat-sen Memorial Hospital, Guangzhou

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guanzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER